KR20250093419A - 형질전환 성장 인자 베타-내성 자연 살해 세포 - Google Patents

형질전환 성장 인자 베타-내성 자연 살해 세포 Download PDF

Info

Publication number
KR20250093419A
KR20250093419A KR1020257019712A KR20257019712A KR20250093419A KR 20250093419 A KR20250093419 A KR 20250093419A KR 1020257019712 A KR1020257019712 A KR 1020257019712A KR 20257019712 A KR20257019712 A KR 20257019712A KR 20250093419 A KR20250093419 A KR 20250093419A
Authority
KR
South Korea
Prior art keywords
cells
cell
tgf
tgfβi
natural killer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257019712A
Other languages
English (en)
Korean (ko)
Inventor
딘 앤소니 리
제니퍼 안 폴츠-스트링펠로우
제나 에드워즈-모세만
Original Assignee
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 filed Critical 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈
Publication of KR20250093419A publication Critical patent/KR20250093419A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020257019712A 2018-01-30 2019-01-29 형질전환 성장 인자 베타-내성 자연 살해 세포 Pending KR20250093419A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862623682P 2018-01-30 2018-01-30
US62/623,682 2018-01-30
PCT/US2019/015617 WO2019152387A1 (en) 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells
KR1020207024676A KR102822300B1 (ko) 2018-01-30 2019-01-29 형질전환 성장 인자 베타-내성 자연 살해 세포

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024676A Division KR102822300B1 (ko) 2018-01-30 2019-01-29 형질전환 성장 인자 베타-내성 자연 살해 세포

Publications (1)

Publication Number Publication Date
KR20250093419A true KR20250093419A (ko) 2025-06-24

Family

ID=67478491

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257019712A Pending KR20250093419A (ko) 2018-01-30 2019-01-29 형질전환 성장 인자 베타-내성 자연 살해 세포
KR1020207024676A Active KR102822300B1 (ko) 2018-01-30 2019-01-29 형질전환 성장 인자 베타-내성 자연 살해 세포

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207024676A Active KR102822300B1 (ko) 2018-01-30 2019-01-29 형질전환 성장 인자 베타-내성 자연 살해 세포

Country Status (12)

Country Link
US (1) US20200368281A1 (https=)
EP (1) EP3746118A4 (https=)
JP (2) JP7591406B2 (https=)
KR (2) KR20250093419A (https=)
CN (1) CN111818941A (https=)
AU (1) AU2019213678B2 (https=)
BR (1) BR112020015490A2 (https=)
CA (1) CA3090096A1 (https=)
IL (2) IL309656A (https=)
MX (1) MX2020008044A (https=)
SG (1) SG11202007288VA (https=)
WO (1) WO2019152387A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021183776A1 (en) * 2020-03-11 2021-09-16 Research Institute At Nationwide Children's Hospital Nk cells and uses thereof for treatment of microbial infections
MX2022012792A (es) * 2020-04-30 2023-02-14 Res Institute At Nationwide Children´S Hospital Superar la inmunosupresion con celulas nk resistentes a tgf-\03b2.
CN120882419A (zh) * 2023-03-02 2025-10-31 全国儿童医院研究所 用于癌症免疫疗法的转化生长因子-β超家族印记的自然杀伤细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
CN105143441B (zh) * 2014-01-13 2019-11-08 张明杰 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法
HK1245080A1 (zh) * 2014-10-27 2018-08-24 University Of Central Florida Research Foundation, Inc. 自然杀伤细胞的方法和组合物
KR20180040706A (ko) * 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
CN116376825A (zh) * 2015-09-14 2023-07-04 明尼苏达大学董事会 表现出适应性表型的nk细胞以及制备和使用方法

Also Published As

Publication number Publication date
EP3746118A1 (en) 2020-12-09
AU2019213678B2 (en) 2025-06-26
JP2025026937A (ja) 2025-02-26
AU2019213678A1 (en) 2020-09-03
IL276374B2 (en) 2024-05-01
IL309656A (en) 2024-02-01
CA3090096A1 (en) 2019-08-08
RU2020127722A (ru) 2022-02-28
WO2019152387A1 (en) 2019-08-08
EP3746118A4 (en) 2021-11-24
IL276374A (en) 2020-09-30
IL276374B1 (en) 2024-01-01
US20200368281A1 (en) 2020-11-26
JP7591406B2 (ja) 2024-11-28
KR102822300B1 (ko) 2025-06-17
CN111818941A (zh) 2020-10-23
SG11202007288VA (en) 2020-08-28
MX2020008044A (es) 2020-12-10
KR20200118449A (ko) 2020-10-15
BR112020015490A2 (pt) 2021-03-23
JP2021512164A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
JP6920644B2 (ja) 幹細胞の免疫制御作用を調節する方法
Stanic et al. IL-10–overexpressing B cells regulate innate and adaptive immune responses
Iking-Konert et al. Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease
Chen et al. IFN-β induces the proliferation of CD4+ CD25+ Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
JP2025026937A (ja) トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞
Torelli et al. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission
Willemen et al. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions
JP6697076B2 (ja) ウイルス抗原特異的ｔ細胞の濃縮および拡大方法
Della Bella et al. Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma
US20250270506A1 (en) T Cells
US20240398695A1 (en) Methods of T Cell Expansion and Activation
JP6334810B2 (ja) Ｉｆｎを用いた非接着培養による樹状細胞の調製方法
RU2830178C2 (ru) Естественные клетки-киллеры, резистентные к трансформирующему ростовому фактору бета
Očadlíková et al. CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2, 3-dioxygenase-1
US20230131219A1 (en) Use of agonists to augment car t function in solid tumors
최가람 A Study on the Mechanism of Effector CD4 T Cell Differentiation by Autocrine TGF-β1
Bürgler Malignant Interaction between B Cells and T Helper Cells
Agbogan et al. CpG-activated Regulatory B-cell Progenitors Alleviate Murine Sclerodermatous Chronic GVHD
Rei Characterization of a pro-tumour role of interleukin-17 producing yδ t cells in ovarian cancer
MUTIS et al. Main Session III
Yasumura et al. Immature NK Cells Suppress Dendritic Cell
Taylor et al. Gene Expression Is Inversely α
Tagaya et al. Interleukin-2-Dependent Mechanisms of

Legal Events

Date Code Title Description
A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201